What is the price target for DRNA stock?
14 analysts have analysed DRNA and the average price target is 37.16 null. This implies a price decrease of -2.78% is expected in the next year compared to the current price of 38.22.
Dicerna Pharmaceuticals Inc (DRNA) Forecast, Price Target & Analyst Ratings
NASDAQ:DRNA
Current stock price
38.22
+0.22 (+0.58%)
At close:
38.24
+0.02 (+0.05%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for Dicerna Pharmaceuticals Inc (DRNA).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- Mar 4, 2022
- Period
- Q4 / 2021
- EPS Estimate
- -$0.55
- Revenue Estimate
- 42.092M
Price Target Details & History
Consensus Price Target and Range
Mean target
$37.16
Upside
-2.78%
From current price of $38.22 to mean target of $37.16, Based on 14 analyst forecasts
Low
$26.26
Median
$39.02
High
$40.16
Price Target Revisions
1 Month
N/A
3 Months
N/A
Price Target Summary
14 Wall Street analysts provided a forecast for the next 12 months for DRNA. The average price target is 37.16 null. This implies a price decrease of -2.78% is expected in the next year compared to the current price of 38.22.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
71.43%
DRNA was analyzed by 14 analysts. The buy percentage consensus is at 71. So analysts seem to be have mildly positive about DRNA.
In the previous month the buy percentage consensus was at a similar level.
DRNA was analyzed by 14 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2021-12-09 | Chardan Capital | Downgrade | Buy -> Neutral |
| 2021-11-19 | RBC Capital | Downgrade | Outperform -> Sector Perform |
| 2021-11-18 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2021-08-11 | Goldman Sachs | Downgrade | Buy -> Neutral |
| 2021-08-10 | Chardan Capital | Maintains | Buy |
| 2021-08-10 | HC Wainwright & Co. | Maintains | Buy |
| 2021-08-09 | Citigroup | Downgrade | Buy -> Neutral |
| 2021-08-06 | RBC Capital | Maintains | Outperform |
| 2021-08-06 | SVB Leerink | Maintains | Outperform |
| 2021-08-06 | Cowen & Co. | Downgrade | Outperform -> Market Perform |
| 2021-08-06 | Truist Securities | Downgrade | Buy -> Hold |
| 2021-08-06 | Goldman Sachs | Maintains | Buy |
| 2021-08-06 | HC Wainwright & Co. | Maintains | Buy |
| 2021-06-23 | HC Wainwright & Co. | Maintains | Buy |
| 2021-04-16 | Goldman Sachs | Initiate | Buy |
| 2021-04-08 | SVB Leerink | Maintains | Outperform |
| 2021-03-02 | Chardan Capital | Maintains | Buy |
| 2021-03-02 | HC Wainwright & Co. | Maintains | Buy |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- Mar 4, 2022
- Period
- Q4 / 2021
- EPS Estimate
- -$0.55
- Revenue Estimate
- 42.092M
- Revenue Q2Q
- 2.76%
- EPS Q2Q
- -12.88%
- Number of Analysts
- 10
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A
Next Earnings Summary
DRNA is expected to report earnings on 3/4/2022. The consensus EPS estimate for the next earnings is -0.55 null and the consensus revenue estimate is 42.09M null.
Full Analyst Estimates 2021 - 2025
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | ||
|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 6.2M 520.00% | 23.9M 285.48% | 164.3M 587.45% | 182.472M 11.06% | 205.938M 12.86% | 175.911M -14.58% | 170.977M -2.80% | 169.506M -0.86% | |
| EBITDA YoY % growth | -60.5M -18.86% | -126.9M -109.75% | -111M 12.53% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -61.3M -18.57% | -128.2M -109.14% | -113.2M 11.70% | N/A | N/A | N/A | N/A | N/A | |
| Operating Margin | -988.71% | -536.40% | -68.90% | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | -1.62 49.85% | -1.76 -8.64% | -1.52 13.64% | -1.72 -13.03% | -2.04 -18.98% | -2.68 -31.18% | -1.97 26.55% | -1.48 25.08% |
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 21 | Q1 / 22 | Q2 / 22 | Q3 / 22 | Q4 / 22 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.55 -12.88% | -0.68 -74.27% | -0.71 -34.59% | -0.50 -126.33% | -0.71 -28.17% |
| Revenue Q2Q % growth | 42.092M 2.76% | 34.695M -27.11% | 33.675M -18.53% | 33.145M -47.35% | 31.722M -24.64% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | N/A | N/A | N/A | N/A | N/A |
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
-20.83%
EPS Next 5 Year
0.58%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
-3.27%
Revenue Next 5 Year
-2.70%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
Dicerna Pharmaceuticals Inc / DRNA Forecast FAQ
Can you provide the upcoming earnings date for Dicerna Pharmaceuticals Inc?
Dicerna Pharmaceuticals Inc (DRNA) will report earnings on 2022-03-04, after the market close.
What are the consensus estimates for Dicerna Pharmaceuticals Inc (DRNA) next earnings?
The consensus EPS estimate for the next earnings of Dicerna Pharmaceuticals Inc (DRNA) is -0.55 null and the consensus revenue estimate is 42.09M null.
Can you provide the consensus rating for Dicerna Pharmaceuticals Inc stock?
The consensus rating for Dicerna Pharmaceuticals Inc (DRNA) is 71.4286 / 100 . This indicates that analysts generally have a positive outlook on the stock.